EU Exclusivity Review: Commission To Assess Impact On 'Skyrocketing' Drug Prices
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis will consider effect of incentives such as data exclusivity and supplementary protection certificates on drug prices, availability and access to medicines; European health ministers also pledge cooperation rein in what they see as the very high prices of some medicines.
You may also be interested in...
EU Report Probes Impact Of IP Incentives On R&D, Market Access
A report for the European Commission’s analysis of pharmaceutical IP incentives finds that the effective protection period has declined over 20 years, but delays to generic entry are still putting pressure on pharmaceutical spending.
EU Report Probes Impact Of IP Incentives On R&D, Market Access
A report for the European Commission’s analysis of pharmaceutical IP incentives finds that the effective protection period has declined over 20 years, but delays to generic entry are still putting pressure on pharmaceutical spending.
Trenches, Silos And Circular Debates: European Health Forum Calls For Collaboration On IP And Medicines Access
A session on intellectual property and its effects on access to new medicines was the subject of heated debate at the recent European Health Forum Gastein conference, with proponents of strong IP protections locking horns with health activists over issues such as the link between IP and high prices.